DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

  • Acute myeloid leukemia (AML), meeting the following criteria:

    • High-risk disease, as evidenced by 1 of the following criteria:

      • In first complete remission (CR) AND AML evolved from prior myelodysplastic syndromes (MDS)
      • High-risk cytogenetics, such as those associated with MDS or complex karyotype
      • Required > 2 courses of prior therapy to obtain CR
      • In second or greater CR

    • Must be in remission by morphology

      • Ineligible if in morphologic relapse/persistent disease, defined as > 5% blasts in normocellular bone marrow OR any percentage of blasts if blasts have unique morphologic markers (e.g., auer rods) or associated cytogenetic markers that allow morphologic relapse to be distinguished

        • Cytogenetic relapse or persistent disease without morphologic relapse is allowed

  • Acute lymphocytic leukemia (ALL), meeting the following criteria:

    • High-risk disease, as evidenced by 1 of the following criteria:

      • In first CR AND has high-risk cytogenetics (e.g., t[9;22] or complex cytogenetic abnormalities)
      • Required > 1 course of prior therapy to obtain CR
      • In second or greater CR

    • Must be in remission by morphology

      • Ineligible if in morphologic relapse/persistent disease, defined as > 5% blasts in normocellular bone marrow OR any percentage of blasts if blasts have unique morphologic markers or associated cytogenetic markers that allow morphologic relapse to be distinguished

        • Cytogenetic relapse or persistent disease without morphologic relapse is allowed
        • A small percentage of blasts that is equivocal between marrow regeneration vs early relapse is allowed provided there are no associated cytogenetic markers consistent with relapse

  • Chronic myelogenous leukemia (CML)

    • No CML in refractory blast crisis unless treated blast crisis in chronic phase

  • Non-Hodgkin's lymphoma (NHL)

    • No intermediate, high-grade, or mantle cell NHL that has progressed on salvage therapy

  • Hodgkin's lymphoma

    • No disease that has progressed on salvage therapy unless disease is stable and non bulky
  • Chronic lymphocytic leukemia
  • Acquired bone marrow failure syndromes
  • Multiple myeloma

  • MDS of all subtypes including refractory anemia if severe pancytopenia or high-risk cytogenetics

    • If blasts ≥ 5%, patient requires induction therapy pretransplant
  • Metastatic breast cancer responsive to recent chemotherapy or in plateau after response to chemotherapy
  • Renal cell cancer
  • Chronic myeloproliferative disorder (e.g., myelofibrosis)
• Donors must be 5/6 or 6/6 related match OR 7-8/8 HLA-A,-B, -C, -DRB1 allele unrelated volunteer match
• Patients with refractory leukemia or MDS may undergo transplant in aplasia after induction or re-induction chemotherapy or radiolabeled antibodies
• No congenital bone marrow failure syndrome
• Hormone receptor status not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) 60-100% (adults) OR Lansky PS 50-100% (pediatric)
• Male or female
• Menopausal status not specified
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No decompensated congestive heart failure
• No uncontrolled arrhythmia
• Ejection fraction ≥ 35%
• DLCO ≥ 30% of predicted
• Albumin > 2.5 g/dL
• AST and ALT < 5 times upper limit of normal (ULN)
• Bilirubin < 3 times ULN
• Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance > 40 mL/min
• No known HIV positivity or evidence of HIV infection
• No active serious infection
• Any recent mold infection (e.g., Aspergillus) must receive therapy for 30 days, have responsive disease, and be cleared by Infectious Disease Department

PRIOR CONCURRENT THERAPY:

• No prior irradiation that would preclude another dose of total body irradiation
• At least 3 months since prior myeloablative transplantation
• No oxygen requirements